CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 140 enrolled / 140 target
Drug / intervention
Depemokimabbiological
Likely dose
100 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05602025
NCT05602025Phase 1CompletedOn Track (3.3/mo)Completion was 32mo ago
CompareCT.gov

An Open-Label, Randomized, Single-Dose, Multicenter, Parallel-Group Study to Compare the Pharmacokinetics of Subcutaneous Depemokimab When Delivered With a Safety Syringe Device or an Autoinjector in Healthy Adult Participants

GlaxoSmithKline·interventional·Posted Nov 1, 2022·Updated Jun 16, 2026

In Brief

A Phase 1 clinical trial evaluating Depemokimab for Asthma. Completed, enrolled 140 participants across 3 sites.

Detailed Summary

This study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Depemokimab administered via a SSD or autoinjector in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsPPD Development, LP

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedNov 1, 2022
Enrollment StartDec 13, 2022
Primary CompletionOct 23, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.7 years ago

Arms & Interventions

Depemokimab via SSDexperimental

Participants received a single subcutaneous dose of 100 milligrams (mg) of depemokimab administered via a Safety Syringe Device (SSD) on Day 1.

Biological: Depemokimab
Depemokimab via autoinjectorexperimental

Participants received a single subcutaneous dose of 100 mg of depemokimab administered via an autoinjector on Day 1.

Biological: Depemokimab

Interventions

Depemokimabbiological

Depemokimab was administered via SSD or autoinjector.